Humacyte Stock Price To Book
| HUMA Stock | USD 4.43 0.15 3.50% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
The current year's Price To Book Ratio is expected to grow to 22.77. Humacyte | Price To Book |
Humacyte Company Price To Book Analysis
Humacyte's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Humacyte Price To Book | 30.28 X |
Most of Humacyte's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Humacyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Humacyte Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Price To Book. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Humacyte Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Humacyte has a Price To Book of 30.2811 times. This is 17.92% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to book for all United States stocks is notably lower than that of the firm.
Humacyte Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Humacyte's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics of similar companies.Humacyte is currently under evaluation in price to book category among its peers.
Humacyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Humacyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Humacyte's managers, analysts, and investors.Environmental | Governance | Social |
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 566.7 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Shares Owned By Insiders | 26.86 % | ||||
| Shares Owned By Institutions | 30.01 % | ||||
| Number Of Shares Shorted | 17.25 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 58.11 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Short Ratio | 5.41 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 570 M | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Humacyte Piotroski F Score and Humacyte Altman Z Score analysis. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.